SCHEMBL3325699

SCHEMBL3325699

Clc1cc(-c2ccco2)nc(Cl)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
POLB P06746 4/20 0.45
MAPT P10636 3/20 0.45
HSD17B10 Q99714 3/20 0.45
KDM4E B2RXH2 3/20 0.45
TDP1 Q9NUW8 3/20 0.45
BLM P54132 2/20 0.45
HPGD P15428 2/20 0.45
ALOX15 P16050 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
MEN1 O00255 1/20 0.45
USP2 O75604 1/20 0.45
LMNA P02545 1/20 0.45
THRB P10828 1/20 0.45
PKM P14618 1/20 0.45
ALOX12 P18054 1/20 0.45
CASP1 P29466 1/20 0.45
PTPN7 P35236 1/20 0.45
BRCA1 P38398 1/20 0.45
RECQL P46063 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3800899 0.82 PDE10A (0.47) ALDH1A1POLBMAPTHSD17B10KDM4E
SCHEMBL718474 0.82 HSP90AA1 (0.54) ALDH1A1MAPTHSD17B10KDM4EBLM
SCHEMBL23162725 0.78 MAPT (0.42) ALDH1A1POLBMAPTHSD17B10KDM4E
SCHEMBL23204380 0.78 DYRK1A (0.45) ALDH1A1POLBMAPTHSD17B10KDM4E
SCHEMBL17336762 0.78 KDM4E (0.60) ALDH1A1POLBMAPTHSD17B10KDM4E
SCHEMBL5016163 0.77 SMN1; SMN2 (0.54) ALDH1A1POLBMAPTHSD17B10KDM4E
SCHEMBL5016286 0.76 KDM4E (0.66) ALDH1A1POLBMAPTHSD17B10KDM4E
SCHEMBL1671400 0.76 ALDH1A1 (0.57) ALDH1A1POLBMAPTHSD17B10KDM4E
SCHEMBL1489493 0.75 POLB (0.56) ALDH1A1POLBMAPTHSD17B10KDM4E
SCHEMBL5026343 0.74 ALDH1A1 (0.57) ALDH1A1POLBMAPTHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3555095-B1 INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF SUNSHINE LAKE PHARMA CO LTD (CN) 2023-04-12 EP disclosed
EP-3362451-B1 INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF SUNSHINE LAKE PHARMA CO LTD (CN) 2023-04-12 EP disclosed
CN-110446711-B Inhibitors of influenza virus replication and uses thereof 广东东阳光药业有限公司 2022-02-15 CN disclosed
US-11225477-B2 Inhibitors of influenza virus replication, application methods and uses thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2022-01-18 US disclosed
US-10987354-B2 Inhibitors of influenza virus replication and uses thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2021-04-27 US disclosed
CN-109748915-B Inhibitors of influenza virus replication and methods of use and uses thereof 广东东阳光药业有限公司 2021-03-26 CN disclosed
CN-107759571-B Inhibitors of influenza virus replication and methods of use and uses thereof 广东东阳光药业有限公司 2021-03-02 CN disclosed
US-10927118-B2 Inhibitors of influenza virus replication and uses thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2021-02-23 US disclosed
CN-108276401-B Inhibitors of influenza virus replication and uses thereof 广东东阳光药业有限公司 2020-12-22 CN disclosed
US-20200339564-A1 INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2020-10-29 US disclosed
CN-108218873-A Inhibitors of influenza viruses replication and application thereof 广东东阳光药业有限公司 2018-06-29 CN disclosed
CN-107759571-A Inhibitors of influenza viruses replication and its application method and purposes 广东东阳光药业有限公司 2018-03-06 CN disclosed
US-20100130473-A1 COMPOUNDS HUMMERSONE MARC GEOFFREY 2010-05-27 US disclosed
US-20100130473-A1 COMPOUNDS HUMMERSONE MARC GEOFFREY 2010-05-27 US disclosed
US-20100130473-A1 COMPOUNDS HUMMERSONE MARC GEOFFREY 2010-05-27 US disclosed
US-7504397-B2 mTOR inhibitor compounds KUDOS PHARMACEUTICALS LTD. (GB) 2009-03-17 US disclosed
US-7504397-B2 mTOR inhibitor compounds KUDOS PHARMACEUTICALS LTD. (GB) 2009-03-17 US disclosed
EP-1877388-A2 HYDRAZINOMETHYL, HYDRAZONOMETHYL AND 5-MEMBERED HETEROCYLIC COMPOUNDS WHICH ACT AS MTOR INHIBITORS AND THEIR USE AS ANTI CANCER AGENTS Kudos Pharmaceuticals Ltd (GB) 2008-01-16 EP disclosed
US-20060199804-A1 Compounds KUDOS PHARMACEUTICALS LTD (GB) 2006-09-07 US disclosed
WO-2006090167-A2 HYDRAZINOMETHYL, HYDR ZONOMETHYL AND 5-MEMBERED HETEROCYLIC COMPOUNDS WHICH ACT AS MTOR INHIBITORS AND THEIR USE AS ANTI CANCER AGENTS KUDOS PHARMACEUTICALS LIMITED (GB) 2006-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10927118-B2 Inhibitors of influenza virus replication and uses thereof EIF2AK2, POLRMT, ZC3HAV1 ALDH1A1 4038/4885POLB 24/4885MAPT 3563/4885
US-20200339564-A1 INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF EIF2AK2, ZC3HAV1, MAVS ALDH1A1 3638/4885POLB 38/4885MAPT 4019/4885
US-10987354-B2 Inhibitors of influenza virus replication and uses thereof ZC3HAV1, MAVS, POLRMT ALDH1A1 3909/4885POLB 35/4885MAPT 3480/4885
US-20060199804-A1 Compounds CA4, CA6, CYP2B6 ALDH1A1 1821/4885POLB 3697/4885MAPT 4672/4885
US-11225477-B2 Inhibitors of influenza virus replication, application methods and uses thereof POLRMT, EIF2AK2, POLM ALDH1A1 3790/4885POLB 12/4885MAPT 4252/4885
US-20100130473-A1 COMPOUNDS CA6, CYP2B6, CA4 ALDH1A1 1677/4885POLB 3845/4885MAPT 4601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.